Compounds > quinazolines
Page last updated: 2024-08-21

quinazolines and Experimental Neoplasms

quinazolines has been researched along with Experimental Neoplasms in 117 studies

Research

Studies (117)

TimeframeStudies, this research(%)All Research%
pre-199013 (11.11)18.7374
1990's8 (6.84)18.2507
2000's39 (33.33)29.6817
2010's51 (43.59)24.3611
2020's6 (5.13)2.80

Authors

AuthorsStudies
Deng, J; Lei, F; Li, J; Liang, Z; Shi, T; Wang, Y; Wang, Z; Yang, X; Zhang, H1
Ahmed, AU; Balyasnikova, IV; Burga, R; Castro, B; Cordero, A; Fares, J; Kanojia, D; Lee-Chang, C; Lesniak, MS; Miska, J; Petrosyan, E; Ramsey, MD; Rashidi, A; Schwartz, CW; Xiao, T; Zhang, P1
Cui, H; Dong, Z; Hou, J; Ke, X; Wang, F; Yang, L; Yin, C; Zhang, K; Zhang, R; Zhong, X1
Benites, J; Buc Calderon, P; Muccioli, GG; Ríos, D; Valderrama, JA1
Fujiwara, Y; Hamada, A; Ohuchi, M; Ryu, S; Shimoi, T; Tamura, K; Yagishita, S; Yonemori, K1
Ahn, YG; Bae, I; Choi, J; Hyung Kim, H; Kim, D; Kim, DK; Kim, J; Kim, M; Kim, YH; Park, B1
Bi, K; Chen, S; Dong, G; Huang, Y; Li, Y; Sheng, C; Wu, S1
Shi, Y; Su, C; Zhao, L; Zheng, Y1
Balaji, KS; Devegowda, PS; Jayarama, S; Kameshwar, VH; Prasanna, DS; Rangappa, KS; Siddalingaiah, L; Swaroop, TR1
Kharbanda, A; Runkle, K; Wang, W; Witze, ES1
Babbar, A; Brehmer, D; Chen, JH; Chen, Y; Darjania, L; Deng, X; Dhanak, D; Ely, T; Feng, J; Firdaus, SJ; Guo, X; Hansen, R; Hu-Lowe, D; Janes, MR; Kessler, LV; Kucharski, JM; Li, LS; Li, S; Liu, Y; Long, YO; Lorenzi, MV; Patricelli, MP; Peters, U; Ren, P; Thach, C; Wang, Y; Wu, T; Yao, Y; Yu, K; Zarieh, A; Zarrinkar, PP; Zhang, J1
Ferrari, M; Gu, J; Hamilton, DJ; Jiang, S; Li, F; Li, Z; Pettigrew, RI; Qiu, Y; Yang, Z1
Anderson, J; Barone, G; Blackledge, MD; Carceller, F; Chesler, L; Clarke, M; Jamin, Y; Jerome, NP; Koers, A; Koh, DM; Marshall, LV; McErlean, CM; McHugh, K; Moreno, L; Pearson, ADJ; Poon, E; Robinson, SP; Sebire, N; Vaidya, SJ; Yuan, Y; Zormpas-Petridis, K1
Chern, JW; Hsin, LW; Hung, PY; Liu, JR; Yu, CW1
Duan, W; Feng, Y; Hei, YY; Mao, S; Sun, H; Wang, J; Xin, M; Zhang, H; Zhang, SQ1
Cai, G; Cai, J; Gao, R; Ji, Q; Li, C; Li, Q; Song, D; Sui, H; Teng, P; Wang, Y; Zhou, L1
Albanese, C; Alzani, R; Amboldi, N; Bungaro, S; Casolaro, A; Cazzaniga, G; Ceruti, R; Cribioli, S; Giussani, U; Golay, J; Introna, M; Losa, M; Marchesi, F; Patton, V; Pesenti, E; Pezzoni, A; Rambaldi, A; Texido, G; Valsasina, B1
Ishiguro, H; Ishiguro, Y; Miyamoto, H1
Chen, JQ; Giaccone, G; Goldsmith, PK; Heldman, MR; Herrmann, MA; Lee, JH; Park, KS; Wang, Y1
Fan, C; Guo, Z; Li, Y; Lin, D; Yang, S; Yang, Y; Zhang, L; Zhao, S; Zhu, J1
Döme, B; Fehniger, TE; Jansson, B; Laurell, T; Marko-Varga, G; Rezeli, M; Végvári, Á; Welinder, C1
Bull, CO; Fracasso, PR; Haegebarth, A; Hentemann, M; Liu, N; Mumberg, D; Rowley, BR; Schatz, CA; Schneider, C; Scott, WJ; Wilhelm, SM; Wilkie, DP; Ziegelbauer, K1
Biersack, B; Ficner, R; Mahal, K; Mueller, T; Resch, M; Schobert, R1
Bergbower, E; Dennis, PA; Dogan, I; Ekmekci, A; Gills, JJ; Kawabata, S; Rudin, CM; Wilson, W1
Deng, ZJ; Dreaden, EC; Hammond, PT; Lee, MJ; Morton, SW; Shah, NJ; Shopsowitz, KE; Siouve, E; Yaffe, MB1
Niessen, HG; Poot, AJ; Schuit, RC; Slobbe, P; Smit, EF; Solca, F; Stehle, G; Stigter-van Walsum, M; van Dongen, GA; Windhorst, AD1
Fu, LW; Huang, LY; Huang, ZC; To, KK; Wang, F; Wang, XK; Xu, JH; Yang, K; Ye, S1
Baumann, M; Ebert, N; Eicheler, W; Gurtner, K; Krause, M; Pfitzmann, D; Zips, D1
Chen, V; Crooks, DR; Ghosh, S; Krishna, MC; Liao, PJ; Linehan, WM; Mannes, PZ; Matsumoto, S; Merino, M; Mitchell, JB; Neckers, L; Pendergast, AM; Ricketts, CJ; Rouault, TA; Sourbier, C; Srinivasan, R; Srivastava, G; Vocke, CD; Wei, MH; Yang, Y1
Kang, BR; Li, Y; Lu, SM; Wang, XM; Xin, MH; Xu, J; Zhang, SQ1
Lin, J; Xue, L; Yin, S; Zhang, C; Zhou, L1
Chen, D; Fan, C; Li, Y; Yang, Y; Zhang, L; Zhao, S; Zheng, Q; Zheng, S; Zhou, H1
Cao, YX; He, YY; Mao, S; Xiao, X; Xie, XX; Xin, MH; Xuan, W; Zhang, S; Zhang, SQ; Zuo, SJ1
Cai, R; Chen, S; Cheng, Y; Du, L; Han, B; Li, M; Lin, Y; Ma, Z; Shi, B; Shi, X; Wu, W; Zhou, Y1
Amoozgar, Z; Batchelor, TT; Batista, A; Chatterjee, S; Datta, M; Duda, DG; Farrar, CT; Fukumura, D; Goveia, J; Huang, Y; Jain, RK; Jung, K; Kamoun, WS; Kirkpatrick, ND; Kloepper, J; Leow, CC; Marijt, KA; Muzikansky, A; Peterson, TE; Seano, G; Snuderl, M; Vardam, T; Xu, L1
Fang, W; Tian, Y; Xue, C; Zhan, J; Zhang, J; Zhang, L; Zhao, Y1
He, J; Huang, C; Li, J; Li, Z; Liu, C; Meng, X; Zhang, L1
Ohyashiki, K; Okabe, S; Sakuta, J; Tanaka, Y; Tauchi, T1
Chen, M; Guo, Y; Huang, J; Jiang, H; Li, M; Xie, Y; Yue, S; Zhang, F; Zhou, G1
Allen, DA; Baskaran, S; Bui, M; Elling, RA; Flanagan, WM; Fung, AD; Hanan, EJ; Harris, S; Heumann, SA; Hoch, U; Jacobs, JW; Lam, J; Lawrence, CE; Lew, W; McDowell, RS; Nannini, MA; O'Brien, T; Oslob, JD; Romanowski, MJ; Shen, W; Silverman, JA; Sopko, MM; Tangonan, BT; Teague, J; Yoburn, JC; Yu, CH; Zhong, M; Zimmerman, KM1
Curtin, NJ; Kyle, S; Mitchell, J; Thomas, HD1
Barr, S; Brown, E; Buck, E; Epstein, D; Eyzaguirre, A; Gibson, NW; Haley, JD; Iwata, KK; Ji, QS; Miglarese, M; Mulvihill, M; O'Connor, M; Pachter, J; Rosenfeld-Franklin, M; Thomson, S; Yao, Y1
Katayama, H; Kishino, D; Kiura, K; Kuyama, S; Ohashi, K; Okada, T; Sato, K; Takigawa, N; Tanimoto, M1
Gaballah, K; Hills, A; Oakley, R; Partridge, M; Ryan, A1
Cerniglia, GJ; Choe, R; Durduran, T; Evans, SM; Hahn, SM; Koch, CJ; Lee, WM; Maity, A; Mick, R; Pore, N; Quon, H; Schultz, S; Sehgal, CM; Tsai, JH; Xing, X; Yodh, AG1
Amornphimoltham, P; Chiorini, JA; Gutkind, JS; Schmidt, M; Weller, ML; Wilson, PA1
Chang, TH; Huang, CP; Lan, CC; Lin, SB; Shih, JY; Su, KY; Tsai, MF; Wu, CP; Wu, SG; Yang, CH; Yang, PC; Yu, SL; Yu, YL1
Asano, K; Ohkuma, H1
Aten, JA; Buist, MR; Eppink, B; Essers, J; Franken, NA; Kanaar, R; Krawczyk, PM; O'Connor, MJ; Odijk, H; Rens, J; Rodermond, H; Soullié, T; Stalpers, LJ; Stap, J; Ten Hagen, TL; van Bree, C; Verhagen, HJ; Zelensky, A1
Kachnic, LA; Powell, SN1
Gilmer, TM; Rusnak, D1
Alferez, D; Davies, BR; Heaton, SP; Heier, A; Holt, SV; Logié, A; Odedra, R; Smith, PD; Wilkinson, RW1
Collins, M; Gore, JC; Halliday, J; Huszar, D; Lawson, D; Loveless, ME; Nadella, MV; Reimer, C; Waterton, JC; Yankeelov, TE1
Farsaci, B; Greiner, JW; Sabzevari, H; Schlom, J; Takai, S1
Feng, ZH; Li, D; Liao, SJ; Shu, Y; Sun, R; Wang, Q; Wei, JJ; Yan, B; Yuan, Y; Zhang, GM; Zhou, YH; Zhu, JH1
Fung, AS; Jonkman, J; Tannock, IF1
Abe, M; Hashimoto, O; Inoue, K; Iwamoto, H; Koga, H; Masuda, H; Nakamura, T; Sata, M; Torimura, T; Ueno, T; Yano, H1
Bokacheva, L; Carlin, S; Halliday, J; Kotedia, K; Koutcher, JA; Le, CH; Reese, M; Ricketts, SA1
Davis, C; Ding, L; Hu, S; Hu, Y; Kang, X; Long, W; Tan, F; Wang, F; Wang, Y; Xie, G; Zhang, DX1
Chang, YL; Chen, HJ; Chen, KF; Cheng, AL; Liu, CY; Shiau, CW; Yu, HC1
Alapati, V; Manjula, SN; Noolvi, MN; Pallavi, KJ; Patel, HM; Satyanarayana, SV; Tippeswamy, BS1
Casanovas, O; Castillo-Ávila, W; Condom, E; Garcia Del Muro, X; Germà, JR; Graupera, M; Hernández-Losa, J; Juliachs, M; Pandiella, A; Piulats, JM; Teixidó, C; Vidal, A; Villanueva, A; Viñals, F1
Buechner, SA; Erne, P; Iezzi, G; Kyriakakis, E; Pfaff, D; Philippova, M; Resink, TJ; Schoenenberger, AW; Spagnoli, GC1
Ajaykumar, R; Babu, PA; Deevi, DS; Kumar, GS; Kumar, KB; Mamidi, NV; Narasimhulu, CP; Prasanna, P; Puranik, RC; Rajagopal, S; Rajagopalan, R; Rao, CS; Rao, CV; Renuka, B; Seshu, KV; Sharma, VM; Subramanyam, D; Venkateswarlu, A1
Bigley, AL; Boffey, SJ; Chester, R; Curry, B; Curwen, JO; Dukes, M; Graham, GA; Hennequin, LF; Hughes, GD; Jackson, JA; Kendrew, J; Musgrove, HL; Ogilvie, DJ; Richmond, GH; Stokes, ES; Thomas, AP; Valentine, PJ; Wadsworth, PF; Wedge, SR1
Ben-David, I; Chisin, R; Freedman, NM; Levitzki, A; Mishani, E; Ortu, G; Rozen, Y1
Bianco, AR; Bianco, C; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; Fontanini, G; Pepe, S; Raben, D; Tortora, G; Troiani, T; Veneziani, BM1
Affleck, K; Alligood, KJ; Gilmer, TM; Keith, BR; Knight, WB; Lackey, K; Mullin, RJ; Murray, DM; Rhodes, N; Rusnak, DW; Wood, ER1
Affleck, K; Cockerill, GS; Gaul, MD; Gilmer, TM; Griffin, RJ; Guntrip, S; Guo, Y; Keith, BR; Knight, WB; Lackey, K; Mullin, RJ; Murray, DM; Rusnak, DW; Smith, K; Tadepalli, S; Wood, ER1
Fredriksson, A; Stone-Elander, S1
Checkley, D; Curry, B; Dukes, M; Kendrew, J; Middleton, B; Tessier, JJ; Waterton, JC; Wedge, SR1
BALDWIN, RW; CUNNINGHAM, GJ; DEAN, HG; PARTRIDGE, MW; SURTEES, SJ; VIPOND, HJ1
Bruneteau, G; Clement, O; Cuenod, CA; de Bazelaire, C; Frija, G; Frouin, F; Pradel, C; Robert, PH; Siauve, N; Tessier, JL; Wedge, SR1
Checkley, D; Kendrew, J; Tessier, JJ; Waterton, JC; Wedge, SR1
Abbott, E; Brown, EN; Colagiovanni, DB; Desjardins, J; Drolet, DW; Emerson, DL1
Brousal, J; Cuneo, K; Fu, A; Geng, L; Hallahan, DE; Hayflick, JS; Himmelfarb, E; Kesicki, EA; Niermann, K; Schueneman, A; Tan, J; Treiberg, J1
Arribas, J; Baselga, J; Cassia, R; Di Cosimo, S; Guzmán, M; Matar, P; Moreno-Bueno, G; Palacios, J; Rodriguez, S; Rojo, F; Tabernero, J1
Brandt, R; Hynes, NE; Littlewood, A; O'Reilly, T; Schnell, C; Sini, P; Wood, J; Wyder, L1
Arao, T; Koizumi, F; Nishio, K; Shiratori, Y; Takeda, M; Takigahira, M; Yanagihara, K1
Ballard, P; Bradbury, RH; Hennequin, LF; Hickinson, DM; Johnson, PD; Kettle, JG; Klinowska, T; Morgentin, R; Ogilvie, DJ; Olivier, A1
Gibbs, DD; Henley, A; Jackman, AL; Raynaud, F; Wood, N; Workman, P1
Ajiki, T; Digiovanni, J; Kawamoto, T; Kiguchi, K; Ruffino, L1
Alvarez, JV; Bulmer, SE; Chen, TH; Feng, W; Frank, DA; Greulich, H; Hahn, WC; Jänne, PA; Meyerson, M; Sellers, WR; Zappaterra, M1
Ariazi, E; Bertucci, A; Grigg, R; Jordan, VC; Lee, ES; Meeke, K; Morris, C; O'Regan, RM; Osipo, C; Sarker, MA1
Goto, H; Matsumori, Y; Nakataki, E; Ryan, AJ; Sone, S; Wedge, SR; Yano, S1
Birle, DC; Hedley, DW1
Fujiwara, M; Ikehara, S; Ikehara, Y; Kodera, Y; Koike, M; Mochizuki, Y; Nakanishi, H; Nakao, A; Tatematsu, M; Yatabe, Y; Yokoyama, H1
Beroukhim, R; Cloughesy, T; DeBiasi, RM; Feng, WL; Gabriel, S; Getz, G; Glatt, KA; Greulich, H; Huang, JH; Kawaguchi, T; Khan, H; King, JC; Leahy, DJ; Lee, JC; Levine, RL; Liau, LM; Linhart, DJ; Mellinghoff, IK; Meyerson, M; Mischel, P; Nelson, SF; Nghiemphu, P; O'Neill, K; Onofrio, R; Paez, JG; Peck, TC; Pieper, RO; Rao, PN; Sawyers, CL; Sellers, WR; Thomas, RK; Vivanco, I; Xu, Q; Yoshimoto, K; Yuza, Y; Ziaugra, L1
Courtright, J; Gorlick, R; Houghton, PJ; Keir, ST; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA; Tajbakhsh, M; Wu, J1
Barrass, NC; Bigley, A; Boyle, FT; Brady, MC; Brown, E; Byth, KF; Crafter, C; Foote, KM; Foster, JR; Green, S; Heaton, SP; Heron, NM; Jung, FH; Keen, NJ; Mortlock, AA; Mundt, KE; Odedra, R; Wedge, SR; Wilkinson, RW1
Acton, DG; Ballard, P; Barlaam, B; Bradbury, RH; Cross, D; Ducray, R; Germain, H; Hudson, K; Klinowska, T; Magnien, F; Ogilvie, DJ; Olivier, A; Ross, HS; Smith, R; Trigwell, CB; Vautier, M; Wright, L1
Cummings, J; Dive, C; Growcott, J; Heaton, SP; Hodgkinson, C; Hughes, A; Mundt, KE; Odedra, R; Sini, P; Ward, TH; Wilkinson, RW1
Amin, DN; Bielenberg, DR; Heymach, JV; Klagsbrun, M; Lifshits, E1
Bertino, JR; Cardenas, RM; Fernandes, DJ; Hynes, JB1
Betit-Yen, K; Gitterman, CO; Lee, G; Luell, S; Prendergast, JS; Skipski, VP; Stock, CC1
Amyx, H; Boytos, CM; Duch, DS; Ferone, R; Smith, GK; Wilson, HR1
Bacquet, RJ; Bartlett, CA; Booth, CL; Deal, J; Herrmann, SM; Howland, EF; Janson, CA; Johnston, A; Jones, TR; Kathardekar, V; Lewis, KK; Matthews, DA; Mazdiyasni, H; Morse, CA; Nguyen, D; Reddy, MR; Smith, WW; Varney, MD; Ward, RW; Webber, S; Webber, SE; Welsh, KM; White, J1
Bridges, AJ; Denny, WA; Dobrusin, EM; Doherty, A; Fry, DW; Greis, KD; Hicks, JL; Hook, KE; Keller, PR; Leopold, WR; Loo, JA; McNamara, DJ; Nelson, JM; Sherwood, V; Smaill, JB; Trumpp-Kallmeyer, S1
Carroll, ML; Discafani, CM; Floyd, MB; Greenberger, LM; Hollander, IJ; Husain, Z; Johnson, BD; Kitchen, D; Malo, MS; May, MK; Minnick, AA; Nilakantan, R; Shen, R; Wang, YF; Wissner, A1
Bridges, AJ; Dykes, DJ; Elliott, WL; Fry, DW; Leopold, WR; Patmore, SJ; Roberts, BJ; Rose, S; Sherwood, V; Vincent, PW; Zhou, H1
Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Pomatico, G; Tortora, G1
Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Cuccato, S; Damiano, V; De Placido, S; Fontanini, G; Tortora, G1
Ahmad, T; Anderson, NG; Bundred, NJ; Chan, K; Dobson, R1
Bertino, JR; Hynes, JB; Moroson, BA; Scanlon, KJ1
Bertino, JR; Cashmore, AR; Elslager, EF; Moroson, BA; Sawicki, WL1
Donsback, RC; Sirotnak, FM1
Gibson, W; Jackman, AL; Jodrell, DI; Stephens, TC1
Bertino, JR; Lin, JT1
Atassi, G; Baron, M; Bissery, MC; Cros, S; Gebel-Servolles, P; Giorgi-Renault, S; Lavelle, F; Paoletti, C; Renault, J1
Osada, Y; Tanaka, NG; Tohgo, A1
Bissery, MC; Corbett, TH; Luk, GD; Mucci-LoRusso, P; Plowman, J; Polin, L; Valeriote, F1
Griswold, DP; Hook, KE; Leopold, WR; Nelson, JM; Roberts, BJ1
Cradock, J; Grillo-Lopez, A; Leyland-Jones, B; O'Dwyer, PJ; Plowman, J; Shoemaker, DD1
Baldwin, RW; Chayen, J; Diengdoh, JV1
Maley, F; Maley, GF1
Carlin, SC; Friedkin, M; Rosenberg, RN; VandeVenter, L1
Marini, JL; Modest, EJ; Nadel, ME; Rosowsky, A1

Reviews

2 review(s) available for quinazolines and Experimental Neoplasms

ArticleYear
PET screening of anticancer drugs. A faster route to drug/target evaluations in vivo.
    Methods in molecular medicine, 2003, Volume: 85

    Topics: Animals; Antineoplastic Agents; Drug Evaluation; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Haplorhini; Humans; Image Processing, Computer-Assisted; Isotope Labeling; Neoplasm Proteins; Neoplasms; Neoplasms, Experimental; Quinazolines; Radiopharmaceuticals; Rats; Tomography, Emission-Computed; Xenograft Model Antitumor Assays

2003
Update on trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties.
    Cancer investigation, 1991, Volume: 9, Issue:2

    Topics: Adult; Aged; Animals; Antineoplastic Agents; Antiprotozoal Agents; Clinical Trials as Topic; Drug Resistance; Female; Folic Acid Antagonists; Humans; Male; Middle Aged; Neoplasms, Experimental; Quinazolines; Trimetrexate

1991

Trials

3 trial(s) available for quinazolines and Experimental Neoplasms

ArticleYear
The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia.
    PloS one, 2013, Volume: 8, Issue:3

    Topics: Adult; Animals; CD56 Antigen; Cell Cycle Proteins; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Experimental; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2013
Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.
    NMR in biomedicine, 2013, Volume: 26, Issue:2

    Topics: Animals; Antineoplastic Agents; Contrast Media; Fluorodeoxyglucose F18; Gadolinium DTPA; HT29 Cells; Humans; Neoplasms, Experimental; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Rats; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Xenograft Model Antitumor Assays

2013
Trimetrexate: a new antifol entering clinical trials.
    Investigational new drugs, 1985, Volume: 3, Issue:1

    Topics: Animals; Biological Availability; Biological Transport; Cells, Cultured; Clinical Trials as Topic; DNA; Dogs; Drug Evaluation, Preclinical; Folic Acid Antagonists; Mice; Neoplasms, Experimental; Nucleosides; Quinazolines; Trimetrexate

1985

Other Studies

112 other study(ies) available for quinazolines and Experimental Neoplasms

ArticleYear
Design, synthesis and bioactivity evaluation of novel evodiamine derivatives with excellent potency against gastric cancer.
    European journal of medicinal chemistry, 2022, Jan-15, Volume: 228

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Quinazolines; Stomach Neoplasms; Structure-Activity Relationship

2022
Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer.
    Proceedings of the National Academy of Sciences of the United States of America, 2022, 01-04, Volume: 119, Issue:1

    Topics: Animals; Antineoplastic Agents, Immunological; Brain Neoplasms; Cell Line, Tumor; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasms, Experimental; Neural Stem Cells; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays

2022
G9a promotes cell proliferation and suppresses autophagy in gastric cancer by directly activating mTOR.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019, Volume: 33, Issue:12

    Topics: Animals; Autophagy; Azepines; Cell Cycle; Cell Line; Cell Proliferation; Cell Survival; Down-Regulation; Female; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Histones; Humans; Mice, SCID; Neoplasms, Experimental; Quinazolines; Stomach Neoplasms; TOR Serine-Threonine Kinases

2019
In Vitro Inhibition of Hsp90 Protein by Benzothiazoloquinazolinequinones Is Enhanced in The Presence of Ascorbate. A Preliminary In Vivo Antiproliferative Study.
    Molecules (Basel, Switzerland), 2020, Feb-20, Volume: 25, Issue:4

    Topics: Animals; Antineoplastic Agents; Ascorbic Acid; Cell Proliferation; HSP90 Heat-Shock Proteins; Humans; MCF-7 Cells; Mice; Neoplasm Proteins; Neoplasms, Experimental; Quinazolines; Xenograft Model Antitumor Assays

2020
Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging.
    Scientific reports, 2020, 09-23, Volume: 10, Issue:1

    Topics: Acetanilides; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

2020
Design, synthesis and biological evaluation of new bivalent quinazoline analogues as IAP antagonists.
    Bioorganic & medicinal chemistry letters, 2021, 02-15, Volume: 34

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dogs; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Inhibitor of Apoptosis Proteins; Mice; Molecular Structure; Neoplasms, Experimental; Quinazolines; Rats; Structure-Activity Relationship

2021
Water-soluble derivatives of evodiamine: Discovery of evodiamine-10-phosphate as an orally active antitumor lead compound.
    European journal of medicinal chemistry, 2021, Aug-05, Volume: 220

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; HCT116 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Phosphates; Quinazolines; Solubility; Structure-Activity Relationship; Water

2021
Chitosan nanoparticle-mediated co-delivery of shAtg-5 and gefitinib synergistically promoted the efficacy of chemotherapeutics through the modulation of autophagy.
    Journal of nanobiotechnology, 2017, Apr-11, Volume: 15, Issue:1

    Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 5; Cell Line, Tumor; Chitosan; Drug Delivery Systems; Female; Gefitinib; Gene Silencing; Humans; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nanoparticles; Neoplasms, Experimental; Quinazolines; RNA, Small Interfering; Transfection

2017
Synthesis, Characterization of 4-Anilino-6,7-Dimethoxy Quinazoline Derivatives as Potential Anti-Angiogenic Agents.
    Anti-cancer agents in medicinal chemistry, 2018, Feb-07, Volume: 17, Issue:14

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Mice; Molecular Docking Simulation; Neoplasms, Experimental; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2

2018
Induced sensitivity to EGFR inhibitors is mediated by palmitoylated cysteine 1025 of EGFR and requires oncogenic Kras.
    Biochemical and biophysical research communications, 2017, 11-04, Volume: 493, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Cocarcinogenesis; Cysteine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lipoylation; MCF-7 Cells; Membrane Proteins; Mutation; Neoplasms, Experimental; Proto-Oncogene Proteins p21(ras); Quinazolines

2017
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
    Cell, 2018, 01-25, Volume: 172, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Female; HCT116 Cells; HEK293 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Mutation; Neoplasms, Experimental; Piperazines; Protein Binding; Proto-Oncogene Proteins p21(ras); Quinazolines

2018
Single-Molecule Force Measurement Guides the Design of Multivalent Ligands with Picomolar Affinity.
    Angewandte Chemie (International ed. in English), 2019, 04-08, Volume: 58, Issue:16

    Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Humans; Ligands; Mice; Molecular Structure; Neoplasms, Experimental; Optical Imaging; Piperidines; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor

2019
MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment.
    Cancer research, 2019, 06-01, Volume: 79, Issue:11

    Topics: Angiogenesis Inhibitors; Animals; Child; Child, Preschool; Contrast Media; Female; Humans; Infant; Magnetic Resonance Imaging; Male; Mice, Transgenic; N-Myc Proto-Oncogene Protein; Neoplasms, Experimental; Neuroblastoma; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome

2019
High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma.
    Biochemical pharmacology, 2019, Volume: 163

    Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Glioblastoma; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Male; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Quinazolines

2019
Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors.
    Bioorganic & medicinal chemistry, 2019, 10-15, Volume: 27, Issue:20

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Sulfonamides; Tumor Cells, Cultured

2019
Development of EGFR-targeted evodiamine nanoparticles for the treatment of colorectal cancer.
    Biomaterials science, 2019, Aug-20, Volume: 7, Issue:9

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Male; Mice; Mice, Inbred ICR; Molecular Structure; Neoplasms, Experimental; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured

2019
Epidermal growth factor receptor tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces subsequent development of interstitial pneumonia.
    Oncotarget, 2013, Volume: 4, Issue:4

    Topics: Antibodies, Neutralizing; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Humans; Interleukin-6; Lung Diseases, Interstitial; Neoplasms, Experimental; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tyrphostins; Up-Regulation

2013
Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Immunoassay; Lung Neoplasms; Lymphatic Metastasis; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasms, Experimental; Oncogene Proteins; Phosphorylation; Protein Kinase Inhibitors; Quinazolines

2013
Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer.
    European journal of medicinal chemistry, 2013, Volume: 69

    Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Male; Mice; Mice, Inbred BALB C; Molecular Structure; Neoplasms; Neoplasms, Experimental; Quinazolines; Rats; Rats, Wistar; Receptor, ErbB-2; Solubility; Structure-Activity Relationship

2013
Experimental models to study drug distributions in tissue using MALDI mass spectrometry imaging.
    Journal of proteome research, 2013, Dec-06, Volume: 12, Issue:12

    Topics: Adenocarcinoma; Animals; Biological Transport; Cholinergic Antagonists; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Microtomy; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; Scopolamine Derivatives; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tiotropium Bromide; Tissue Culture Techniques; Tumor Microenvironment

2013
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:11

    Topics: Administration, Intravenous; Animals; Apoptosis; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasms; Neoplasms, Experimental; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Rats, Nude; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2013
Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels.
    ChemMedChem, 2014, Volume: 9, Issue:4

    Topics: Animals; Antineoplastic Agents; Blood Vessels; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Endothelial Cells; HCT116 Cells; HT29 Cells; Humans; MCF-7 Cells; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Neovascularization, Pathologic; Quinazolines; Structure-Activity Relationship

2014
SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines.
    Lung cancer (Amsterdam, Netherlands), 2014, Volume: 85, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Lung Neoplasms; Mice, Transgenic; Mutation; Neoplasms, Experimental; Quinazolines; SOXB1 Transcription Factors

2014
A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways.
    Science signaling, 2014, May-13, Volume: 7, Issue:325

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Carriers; Erlotinib Hydrochloride; Female; Liposomes; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms, Experimental; Quinazolines

2014
Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors.
    Nuclear medicine and biology, 2014, Volume: 41, Issue:9

    Topics: Afatinib; Animals; Cell Line, Tumor; ErbB Receptors; Fluorine Radioisotopes; Isotope Labeling; Metabolic Clearance Rate; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Organ Specificity; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution

2014
Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.
    Oncotarget, 2014, Dec-15, Volume: 5, Issue:23

    Topics: Afatinib; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Immunohistochemistry; In Vitro Techniques; Male; Mice; Mice, Inbred BALB C; Neoplasm Proteins; Neoplasms, Experimental; Quinazolines; Real-Time Polymerase Chain Reaction; Topotecan; Xenograft Model Antitumor Assays

2014
Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts.
    Radiation oncology (London, England), 2014, Dec-02, Volume: 9

    Topics: Afatinib; Animals; Cell Line, Tumor; Chemoradiotherapy; Dose Fractionation, Radiation; ErbB Receptors; Female; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Quinazolines; Radiation-Sensitizing Agents; Transplantation, Heterologous; Xenograft Model Antitumor Assays

2014
Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer.
    Cancer cell, 2014, Dec-08, Volume: 26, Issue:6

    Topics: Animals; Cell Line, Tumor; Cell Nucleus; Fumarate Hydratase; Fumarates; Gene Expression Regulation, Neoplastic; Glycolysis; HEK293 Cells; Humans; Kidney Neoplasms; Mice; Neoplasms, Experimental; NF-E2-Related Factor 2; Oxidative Stress; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-abl; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays

2014
Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo.
    European journal of medicinal chemistry, 2015, Volume: 96

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; MCF-7 Cells; Mice; Molecular Docking Simulation; Molecular Structure; Neoplasms, Experimental; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured

2015
Design, synthesis and biological activities of novel oxazolo[4,5-g]quinazolin-2(1H)-one derivatives as EGFR inhibitors.
    European journal of medicinal chemistry, 2015, Aug-28, Volume: 101

    Topics: Animals; Antineoplastic Agents; Benzoxazoles; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Mice; Mice, SCID; Neoplasms, Experimental; Quinazolines; Structure-Activity Relationship

2015
Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors.
    European journal of medicinal chemistry, 2015, Sep-18, Volume: 102

    Topics: Afatinib; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2015
Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents.
    Bioorganic & medicinal chemistry, 2016, Jan-15, Volume: 24, Issue:2

    Topics: Amines; Aniline Compounds; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Urea

2016
Discovery of the First Environment-Sensitive Near-Infrared (NIR) Fluorogenic Ligand for α1-Adrenergic Receptors Imaging in Vivo.
    Journal of medicinal chemistry, 2016, Mar-10, Volume: 59, Issue:5

    Topics: Animals; Binding Sites; Carbocyanines; Cell Line, Tumor; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Drug Discovery; Fluorescence; Fluorescent Dyes; HEK293 Cells; Humans; Ligands; Mice; Molecular Structure; Neoplasms, Experimental; Piperazine; Piperazines; Quinazolines; Receptors, Adrenergic, alpha-1; Structure-Activity Relationship

2016
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
    Proceedings of the National Academy of Sciences of the United States of America, 2016, Apr-19, Volume: 113, Issue:16

    Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Drug Screening Assays, Antitumor; Glioblastoma; Macrophages; Mice; Neoplasm Proteins; Neoplasms, Experimental; Neovascularization, Pathologic; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Ribonuclease, Pancreatic

2016
In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms, Experimental; Quinazolines; Structure-Activity Relationship

2016
Quinazoline derivative QPB-15e stabilizes the c-myc promoter G-quadruplex and inhibits tumor growth in vivo.
    Oncotarget, 2016, Jun-07, Volume: 7, Issue:23

    Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; G-Quadruplexes; Genes, myc; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Promoter Regions, Genetic; Proto-Oncogene Mas; Proto-Oncogene Proteins c-myc; Quinazolines; Xenograft Model Antitumor Assays

2016
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.
    Oncotarget, 2016, Aug-16, Volume: 7, Issue:33

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasms, Experimental; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinazolines

2016
miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 85

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation; Gene Silencing; Humans; Mice; Mice, Nude; MicroRNAs; Neoplasms, Experimental; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Zinc Finger E-box-Binding Homeobox 1

2017
Discovery of a potent and selective aurora kinase inhibitor.
    Bioorganic & medicinal chemistry letters, 2008, Sep-01, Volume: 18, Issue:17

    Topics: Animals; Antineoplastic Agents; Aurora Kinases; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Structure-Activity Relationship; Thiazoles

2008
Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
    The British journal of radiology, 2008, Volume: 81 Spec No 1

    Topics: Animals; Azulenes; Benzodiazepines; BRCA2 Protein; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; Enzyme Inhibitors; Female; Mice; Mice, Nude; Neoplasms, Experimental; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Recombination, Genetic

2008
Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
    Cancer research, 2008, Oct-15, Volume: 68, Issue:20

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Feedback, Physiological; Female; Humans; Imidazoles; Insulin Receptor Substrate Proteins; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasms, Experimental; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor, IGF Type 1; Signal Transduction

2008
Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice.
    Lung cancer (Amsterdam, Netherlands), 2009, Volume: 65, Issue:3

    Topics: Animals; Antineoplastic Agents; Carcinogens, Environmental; Cell Growth Processes; Cell Line, Tumor; Cell Transformation, Neoplastic; ErbB Receptors; Female; Gefitinib; Lung; Lung Neoplasms; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Nitrosamines; Pulmonary Fibrosis; Quinazolines; Smoking; Tumor Burden

2009
The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues.
    British journal of cancer, 2009, Aug-04, Volume: 101, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Female; Mice; Mice, Inbred C57BL; Neoplasm, Residual; Neoplasms, Experimental; Quinazolines; Triazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2009
Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy.
    PloS one, 2009, Aug-06, Volume: 4, Issue:8

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Neoplasms, Experimental; Oxygen; Quinazolines; Vascular Endothelial Growth Factor A

2009
Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6.
    Nature medicine, 2010, Volume: 16, Issue:6

    Topics: Animals; Cell Line, Tumor; Dependovirus; ErbB Receptors; Female; Gefitinib; Gene Expression; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Isoantigens; Mice; Mice, Nude; Neoplasms, Experimental; Quinazolines; Receptors, Virus; Transduction, Genetic; Tyrphostins

2010
Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.
    American journal of respiratory and critical care medicine, 2011, Apr-15, Volume: 183, Issue:8

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Knockout Techniques; Humans; Lung Neoplasms; Mice; Neoplasms, Experimental; Quinazolines; Snail Family Transcription Factors; Transcription Factors

2011
Epithelial growth factor receptor tyrosine kinase inhibitor prevents infiltration and cerebrospinal fluid dissemination in malignant glioma: an experimental study.
    Neurosurgery, 2011, Volume: 69, Issue:2

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Cadherins; Cell Line; Enzyme Inhibitors; ErbB Receptors; Glioma; Male; Neoplasms, Experimental; Quinazolines; Rats; Rats, Sprague-Dawley; Tyrphostins; Up-Regulation

2011
Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.
    Proceedings of the National Academy of Sciences of the United States of America, 2011, Jun-14, Volume: 108, Issue:24

    Topics: Animals; Benzoquinones; BRCA2 Protein; Cell Line; Cell Line, Tumor; Cells, Cultured; DNA Repair; DNA-Binding Proteins; Embryonic Stem Cells; Female; HeLa Cells; Hot Temperature; Humans; Immunoblotting; Lactams, Macrocyclic; Mice; Mice, Nude; Neoplasms, Experimental; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolines; Rats; Recombination, Genetic; RNA Interference; Transplantation, Heterologous; Tumor Burden

2011
Homologous recombination research is heating up and ready for therapy.
    Proceedings of the National Academy of Sciences of the United States of America, 2011, Jun-14, Volume: 108, Issue:24

    Topics: Animals; Benzoquinones; BRCA2 Protein; Cell Line, Tumor; DNA Repair; DNA-Binding Proteins; Hot Temperature; Humans; Immunoblotting; Lactams, Macrocyclic; Mice; Neoplasms, Experimental; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolines; Rats; Recombination, Genetic; RNA Interference; Transplantation, Heterologous; Tumor Burden

2011
The discovery of lapatinib (GW572016).
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:11

    Topics: Animals; Antineoplastic Agents; Cell Division; Enzyme Inhibitors; ErbB Receptors; Female; Furans; Humans; Neoplasms, Experimental; Quinazolines; Receptor, ErbB-2

2011
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
    British journal of cancer, 2012, Feb-28, Volume: 106, Issue:5

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Docetaxel; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Neoplasms, Experimental; Organophosphates; Protein Kinase Inhibitors; Quinazolines; Taxoids; Temozolomide; Xenograft Model Antitumor Assays

2012
Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology.
    Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Janus Kinase 1; Janus Kinase 2; Magnetic Resonance Imaging; Mice; Mice, Nude; Neoplasms, Experimental; Pyrazoles; Pyrimidines; Quinazolines; Xenograft Model Antitumor Assays

2012
Distinct effects of saracatinib on memory CD8+ T cell differentiation.
    Journal of immunology (Baltimore, Md. : 1950), 2012, May-01, Volume: 188, Issue:9

    Topics: Animals; Antigens, Viral; Benzodioxoles; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Differentiation; Cell Line, Tumor; Humans; Hyaluronan Receptors; Immunologic Memory; Influenza A virus; Influenza Vaccines; Interferon-gamma; L-Selectin; Mice; Mice, Transgenic; Neoplasms, Experimental; Quinazolines; src-Family Kinases; Viral Proteins

2012
Targeting nuclear factor-κB suppresses the negative effect of toll-like receptor 4 signaling on antimetastasis therapy based on targeting αvβ3.
    Cancer science, 2012, Volume: 103, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Movement; Female; Fibronectins; Integrin alphaVbeta3; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasms, Experimental; NF-kappa B; Quinazolines; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Survival Analysis; Toll-Like Receptor 4

2012
Quantitative immunohistochemistry for evaluating the distribution of Ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with paclitaxel.
    Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Female; Gefitinib; Humans; Immunohistochemistry; Ki-67 Antigen; Mice; Mice, Nude; Neoplasms, Experimental; Paclitaxel; Quinazolines; Xenograft Model Antitumor Assays

2012
Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jul-15, Volume: 18, Issue:14

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Mice; Mice, Nude; Neoplasms, Experimental; Phosphorylation; Piperidines; Prognosis; Quinazolines; Vascular Endothelial Growth Factor Receptor-2

2012
Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors.
    Bioorganic & medicinal chemistry letters, 2012, Oct-01, Volume: 22, Issue:19

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Crown Ethers; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Mice; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; Rats; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2012
Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
    Biochemical pharmacology, 2013, Feb-01, Volume: 85, Issue:3

    Topics: Animals; Apoptosis; Autoantigens; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Membrane Proteins; Mice; Mice, Nude; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering

2013
In vivo anti-tumour activity of novel Quinazoline derivatives.
    European review for medical and pharmacological sciences, 2012, Volume: 16, Issue:13

    Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Female; Mice; Neoplasms, Experimental; Quinazolines

2012
ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.
    International journal of cancer, 2013, Volume: 133, Issue:1

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Carcinoma, Embryonal; Cell Survival; Cetuximab; Choriocarcinoma; Endodermal Sinus Tumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoprecipitation; Lapatinib; Male; Mice; Mice, Nude; Neoplasms, Experimental; Neoplasms, Germ Cell and Embryonal; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Receptor, ErbB-3; Teratocarcinoma; Testicular Neoplasms; Transplantation, Heterologous

2013
T-cadherin loss promotes experimental metastasis of squamous cell carcinoma.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:8

    Topics: Animals; Cadherins; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Endothelial Cells; ErbB Receptors; Gefitinib; Human Umbilical Vein Endothelial Cells; Humans; Immunoblotting; Keratinocytes; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Microscopy, Confocal; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Skin Neoplasms; Transendothelial and Transepithelial Migration; Transplantation, Heterologous

2013
Novel indolo[2,1-b]quinazoline analogues as cytostatic agents: synthesis, biological evaluation and structure-activity relationship.
    Bioorganic & medicinal chemistry letters, 2002, Sep-02, Volume: 12, Issue:17

    Topics: Animals; Antineoplastic Agents; Biological Availability; Cell Division; Drug Screening Assays, Antitumor; Humans; Indoles; Male; Mice; Neoplasms, Experimental; Quinazolines; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured

2002
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
    Cancer research, 2002, Aug-15, Volume: 62, Issue:16

    Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Division; Endothelial Growth Factors; Enzyme Inhibitors; Female; Humans; Lymphokines; Male; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Piperidines; Quinazolines; Rats; Rats, Wistar; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays

2002
Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug.
    International journal of cancer, 2002, Oct-01, Volume: 101, Issue:4

    Topics: Acrylamides; Animals; Antineoplastic Agents; Blotting, Western; Carbon Radioisotopes; Disease Models, Animal; Enzyme Inhibitors; ErbB Receptors; Humans; Isotope Labeling; Liver; Male; Neoplasm Transplantation; Neoplasms, Experimental; Phosphorylation; Quinazolines; Rats; Receptor Protein-Tyrosine Kinases; Tissue Distribution; Tomography, Emission-Computed; Tumor Cells, Cultured

2002
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:10

    Topics: Animals; Antineoplastic Agents; bcl-X Protein; Blotting, Western; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiation, Ionizing; Survival Rate; Tumor Cells, Cultured

2002
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
    Molecular cancer therapeutics, 2001, Volume: 1, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Division; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; Fibroblasts; Furans; Humans; Infant, Newborn; Mice; Mice, Nude; Mice, SCID; Neoplasms, Experimental; Phosphorylation; Precipitin Tests; Quinazolines; Receptor, ErbB-2; Signal Transduction; Skin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2001
Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.
    Bioorganic & medicinal chemistry letters, 2003, Feb-24, Volume: 13, Issue:4

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Inhibitory Concentration 50; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Transplantation, Heterologous

2003
Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts.
    Magnetic resonance imaging, 2003, Volume: 21, Issue:5

    Topics: Animals; Contrast Media; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Quinazolines; Transplantation, Heterologous; Triazoles; Vascular Endothelial Growth Factor A

2003
FURTHER STUDIES ON THE INFLUENCE OF PERIPHERAL RING SUBSTITUTION ON THE CARCINOGENICITY OF TRICYCLOQUINAZOLINE.
    Biochemical pharmacology, 1965, Volume: 14

    Topics: Carcinogens; Chemistry, Pharmaceutical; Heterocyclic Compounds; Mice; Neoplasms, Experimental; ortho-Aminobenzoates; Papilloma; Pharmacology; Quinazolines; Research; Skin Neoplasms; Toxicology

1965
Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media.
    Magnetic resonance imaging, 2003, Volume: 21, Issue:8

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Capillary Permeability; Cell Line, Tumor; Contrast Media; Magnetic Resonance Angiography; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Quinazolines; Triazoles; Vascular Endothelial Growth Factor A

2003
Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.
    British journal of cancer, 2003, Nov-17, Volume: 89, Issue:10

    Topics: Adenocarcinoma; Animals; Capillary Permeability; Contrast Media; Dose-Response Relationship, Drug; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Mice; Neoplasms, Experimental; Piperidines; Prostatic Neoplasms; Quinazolines; Reproducibility of Results; Signal Transduction; Transplantation, Heterologous; Vascular Endothelial Growth Factor A

2003
Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice.
    The Journal of pharmacology and experimental therapeutics, 2004, Volume: 309, Issue:3

    Topics: Animals; Antineoplastic Agents; Biological Availability; Carbon Radioisotopes; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Enzyme Inhibitors; Humans; Indoles; Isoindoles; Liposomes; Metabolic Clearance Rate; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Quinazolines; Thymidylate Synthase; Tissue Distribution; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2004
A specific antagonist of the p110delta catalytic component of phosphatidylinositol 3'-kinase, IC486068, enhances radiation-induced tumor vascular destruction.
    Cancer research, 2004, Jul-15, Volume: 64, Issue:14

    Topics: Animals; Catalytic Domain; Cell Movement; Cell Survival; Cells, Cultured; Endothelium, Vascular; Enzyme Inhibitors; Humans; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents

2004
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Oct-01, Volume: 10, Issue:19

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Dose-Response Relationship, Drug; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasms, Experimental; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays

2004
The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jun-15, Volume: 11, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Coculture Techniques; Drug Synergism; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Fluorescent Antibody Technique; Gefitinib; Humans; Immunoblotting; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Pyridines; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor A

2005
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model.
    International journal of cancer, 2006, Jan-15, Volume: 118, Issue:2

    Topics: Biomarkers, Tumor; Carcinoma, Signet Ring Cell; Gene Expression Profiling; Humans; Neoplasm Metastasis; Neoplasms, Experimental; Peritoneal Neoplasms; Piperidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Tumor Cells, Cultured

2006
5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase.
    Bioorganic & medicinal chemistry letters, 2005, Oct-01, Volume: 15, Issue:19

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Carrier Proteins; Enzyme Inhibitors; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Mice; Neoplasms, Experimental; Quinazolines; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Burden

2005
A liquid chromatographic-tandem mass spectrometric method for the determination of two selective thymidylate synthase inhibitors, BGC945 and BGC638, in mouse plasma.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2005, Sep-25, Volume: 824, Issue:1-2

    Topics: Animals; Calibration; Chromatography, Liquid; Enzyme Inhibitors; Humans; Injections, Intravenous; KB Cells; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Neoplasms, Experimental; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Thymidylate Synthase

2005
Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-01, Volume: 11, Issue:15

    Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Blotting, Western; Body Weight; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Enzyme Inhibitors; ErbB Receptors; Gallbladder; Gallbladder Neoplasms; Gefitinib; Humans; In Situ Nick-End Labeling; MAP Kinase Signaling System; Mice; Mice, Transgenic; Microscopy, Fluorescence; Neoplasms, Experimental; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Tolonium Chloride

2005
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
    PLoS medicine, 2005, Volume: 2, Issue:11

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Genetic Therapy; Humans; Mice; Mice, Nude; Mutation; Neoplasms, Experimental; NIH 3T3 Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Shc Signaling Adaptor Proteins; Src Homology 2 Domain-Containing, Transforming Protein 1; STAT3 Transcription Factor; Transfection; Tumor Stem Cell Assay

2005
Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Apr-01, Volume: 12, Issue:7 Pt 1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Quinazolines; Raloxifene Hydrochloride; RNA, Messenger; Structure-Activity Relationship; Transplantation, Heterologous; Trastuzumab; Xenograft Model Antitumor Assays

2006
ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.
    Oncology research, 2006, Volume: 16, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Piperidines; Pleural Effusion, Malignant; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2

2006
Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:10

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Epidermal Growth Factor; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Neoplasms, Experimental; Phosphorylation; Quinazolines; Ribosomal Protein S6; Signal Transduction; Sirolimus; Transplantation, Heterologous; Uterine Cervical Neoplasms

2006
Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis.
    British journal of cancer, 2006, Dec-04, Volume: 95, Issue:11

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Liver Neoplasms; Male; Mice; Mice, Nude; Neoplasms, Experimental; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms

2006
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
    PLoS medicine, 2006, Volume: 3, Issue:12

    Topics: Animals; Astrocytes; Binding Sites; Cell Line, Tumor; Cell Survival; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Nude; Models, Molecular; Mutation, Missense; Neoplasms, Experimental; NIH 3T3 Cells; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transfection

2006
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Humans; Leukemia, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Proteins; Neoplasms, Experimental; Neovascularization, Pathologic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quinazolines; Random Allocation; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays

2008
AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jun-15, Volume: 13, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase B; Aurora Kinases; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Humans; Mice; Mice, Nude; Neoplasms, Experimental; Organophosphates; Protein Serine-Threonine Kinases; Quinazolines; Rats; Transplantation, Heterologous

2007
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
    Bioorganic & medicinal chemistry letters, 2008, Mar-15, Volume: 18, Issue:6

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dogs; Epidermal Growth Factor; ErbB Receptors; Ether-A-Go-Go Potassium Channels; Female; Hepatocytes; Humans; Indazoles; Keratinocytes; Lapatinib; Male; Metabolic Clearance Rate; Mice; Mice, Nude; Mice, SCID; Microsomes; Molecular Structure; Neoplasms, Experimental; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Receptor, ErbB-2; Survival Rate; Xenograft Model Antitumor Assays

2008
Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Enzyme-Linked Immunosorbent Assay; Keratin-18; Male; Neoplasms, Experimental; Organophosphates; Quinazolines; Rats; Rats, Nude

2008
Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
    Microvascular research, 2008, Volume: 76, Issue:1

    Topics: Animals; Cell Line; Cell Line, Tumor; Cell Proliferation; Cinnamates; Endothelial Cells; Endothelium, Vascular; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Neuropilin-1; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transplantation, Heterologous; Tyrphostins; Vascular Endothelial Growth Factor Receptor-2

2008
Effects of 5,8-dideazaisopteroylglutamate and its possible tri-gamma-glutamyl metabolite (5,8-dideazaisoPteGlu3) on colon adenocarcinoma, and the folate dependent enzymes thymidylate synthase and dihydrofolate reductase.
    Advances in experimental medicine and biology, 1983, Volume: 163

    Topics: Adenocarcinoma; Animals; Cell Line; Colonic Neoplasms; DNA Replication; Drug Resistance; Female; Humans; Kinetics; Leukemia; Methotrexate; Methyltransferases; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Peptide Synthases; Quinazolines; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase

1983
Possible relationship between glycosphingolipids and the formation of metastasis in certain human experimental tumors.
    Journal of the National Cancer Institute, 1980, Volume: 65, Issue:2

    Topics: Animals; Carcinoma, Squamous Cell; Chick Embryo; Gangliosides; Glycosphingolipids; Humans; Neoplasm Metastasis; Neoplasms, Experimental; Quinazolines; Sarcoma; Thiazoles

1980
Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid.
    Cancer research, 1995, Dec-15, Volume: 55, Issue:24

    Topics: Animals; Body Weight; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Folic Acid; Humans; Indoles; Intestinal Diseases; Isoindoles; Leucovorin; Mice; Neoplasms, Experimental; Osteosarcoma; Quinazolines; Thymidylate Synthase; Tumor Cells, Cultured

1995
Structure-based design of substituted diphenyl sulfones and sulfoxides as lipophilic inhibitors of thymidylate synthase.
    Journal of medicinal chemistry, 1997, Feb-28, Volume: 40, Issue:5

    Topics: Animals; Antineoplastic Agents; Cell Division; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Escherichia coli; Humans; Magnetic Resonance Spectroscopy; Mice; Models, Molecular; Molecular Conformation; Molecular Structure; Neoplasms, Experimental; Quinazolines; Structure-Activity Relationship; Sulfones; Sulfoxides; Thymidylate Synthase; Tumor Cells, Cultured

1997
Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.
    Proceedings of the National Academy of Sciences of the United States of America, 1998, Sep-29, Volume: 95, Issue:20

    Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Line; Cysteine; Enzyme Inhibitors; ErbB Receptors; Humans; Mice; Mice, Nude; Models, Molecular; Mutagenesis, Site-Directed; Neoplasm Transplantation; Neoplasms, Experimental; Protein Conformation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Recombinant Fusion Proteins; Transplantation, Heterologous; Tumor Cells, Cultured

1998
Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785).
    Biochemical pharmacology, 1999, Apr-15, Volume: 57, Issue:8

    Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Division; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Female; Mice; Mice, Nude; Models, Molecular; Neoplasm Transplantation; Neoplasms, Experimental; Phosphorylation; Quinazolines; Tumor Cells, Cultured

1999
Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:3

    Topics: 3T3 Cells; Animals; Antineoplastic Agents; Area Under Curve; Drug Administration Routes; Drug Administration Schedule; Enzyme Inhibitors; ErbB Receptors; Humans; Infusion Pumps, Implantable; Liver; Mice; Mice, Inbred ICR; Mice, Nude; Mice, SCID; Neoplasm Transplantation; Neoplasms, Experimental; Phosphorylation; Quinazolines; Receptor Protein-Tyrosine Kinases; Transplantation, Heterologous; Treatment Outcome; Tumor Cells, Cultured

2000
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Survival Rate; Taxoids; Thiophenes; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured

2000
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Synergism; Endothelial Growth Factors; ErbB Receptors; Female; Fibroblast Growth Factor 2; Gefitinib; Growth Substances; Humans; Immunohistochemistry; Inhibitory Concentration 50; Lymphokines; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines; Transforming Growth Factor alpha; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays

2001
ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression.
    International journal of cancer, 2001, Dec-15, Volume: 94, Issue:6

    Topics: Cell Division; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Mitogen-Activated Protein Kinases; Neoplasms, Experimental; Phosphorylation; Quinazolines; Tumor Cells, Cultured

2001
Quinazoline analogues of folic acid as inhibitors of thymidylate synthetase from bacterial and mammalian sources.
    Molecular pharmacology, 1979, Volume: 16, Issue:1

    Topics: Animals; Cell Division; Folic Acid; In Vitro Techniques; Lacticaseibacillus casei; Leukemia L1210; Methyltransferases; Mice; Neoplasms, Experimental; Quinazolines; Structure-Activity Relationship; Thymidylate Synthase

1979
2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (tmq), a potent non-classical folate antagonist inhibitor--I effect on dihydrofolate reductase and growth of rodent tumors in vitro and in vivo.
    Biochemical pharmacology, 1979, Jun-15, Volume: 28, Issue:12

    Topics: Animals; Antineoplastic Agents; Folic Acid Antagonists; Humans; In Vitro Techniques; Leukemia L1210; Mice; Neoplasms, Experimental; Quinazolines

1979
Further evidence for a basis of selective activity and relative responsiveness during antifolate therapy of murine tumors.
    Cancer research, 1975, Volume: 35, Issue:7

    Topics: Aminopterin; Animals; Aspartic Acid; Carcinoma, Ehrlich Tumor; Chick Embryo; DNA, Neoplasm; Folic Acid Antagonists; Intestine, Small; Leukemia L1210; Liver; Lymphoma; Methotrexate; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Quinazolines; Sarcoma 180; Tetrahydrofolate Dehydrogenase; Time Factors

1975
ICI D1694, an inhibitor of thymidylate synthase for clinical study.
    Advances in experimental medicine and biology, 1991, Volume: 309A

    Topics: Animals; Breast Neoplasms; Cell Line; Cell Survival; Drug Screening Assays, Antitumor; Female; Folic Acid Antagonists; Humans; Leukemia L1210; Mice; Neoplasms, Experimental; Quinazolines; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured

1991
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
    Journal of medicinal chemistry, 1991, Volume: 34, Issue:1

    Topics: Animals; Antineoplastic Agents; Aziridines; Breast Neoplasms; Cell Division; Cell Line; Drug Screening Assays, Antitumor; Female; Humans; Leukemia L1210; Leukemia, Experimental; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Molecular Structure; Neoplasms, Experimental; Quinazolines; Sarcoma, Experimental; Structure-Activity Relationship

1991
Inhibitory effects of DN-9693 on platelet-enhanced tumor cell attachment to cultured endothelium.
    Invasion & metastasis, 1990, Volume: 10, Issue:1

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Platelets; Calcium; Cells, Cultured; Endothelium, Vascular; Lung Neoplasms; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Neoplasms, Experimental; Platelet Activation; Platelet Aggregation Inhibitors; Pulmonary Artery; Quinazolines; Tumor Cells, Cultured

1990
Activity of batracylin (NSC-320846) against solid tumors of mice.
    Investigational new drugs, 1989, Volume: 7, Issue:4

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Intraductal, Noninfiltrating; Cell Survival; Cells, Cultured; Colonic Neoplasms; Drug Administration Schedule; Drug Screening Assays, Antitumor; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Pancreatic Neoplasms; Quinazolines; Tumor Cells, Cultured

1989
Cell cycle effects of trimetrexate (CI-898).
    Cancer chemotherapy and pharmacology, 1986, Volume: 16, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Survival; Cells, Cultured; Cricetinae; Demecolcine; Drug Evaluation, Preclinical; Female; Flow Cytometry; Injections, Intraperitoneal; Interphase; Leukemia L1210; Methotrexate; Mice; Neoplasms, Experimental; Ovary; Quinazolines; Trimetrexate

1986
Histochemical comparison of the effects of a carcinogenic and a non-carcinogenic derivative of tricycloquinazoline.
    The British journal of dermatology, 1970, Volume: 82, Issue:1

    Topics: Animals; Carcinogens; DNA; Electron Transport Complex IV; Glycerolphosphate Dehydrogenase; Histocytochemistry; Hyperplasia; L-Lactate Dehydrogenase; Mice; Neoplasms, Experimental; Phosphogluconate Dehydrogenase; Quinazolines; Skin; Skin Neoplasms; Succinate Dehydrogenase; Sulfhydryl Compounds

1970
The apparent induction of thymidylate synthetase by amethopterin.
    Annals of the New York Academy of Sciences, 1971, Nov-30, Volume: 186

    Topics: Animals; Aspartic Acid; Benzoates; Carcinoma, Hepatocellular; Enzyme Induction; Folic Acid; Hepatectomy; Liver; Liver Neoplasms; Liver Regeneration; Methotrexate; Methyltransferases; Neoplasms, Experimental; Quinazolines; Rats; Thymine Nucleotides; Uracil Nucleotides

1971
Quinazoline antifolates as inhibitors of growth, dihydrofolate reductase, and thymidylate synthetase of mouse neuroblastoma cells in culture.
    Molecular pharmacology, 1974, Volume: 10, Issue:2

    Topics: Animals; Cells, Cultured; Chromatography, Paper; Folic Acid Antagonists; Growth; Kinetics; Leucovorin; Methyltransferases; Mice; Neoplasms, Experimental; Neuroblastoma; Quinazolines; Thymidine; Thymidylate Synthase

1974
Quinazolines. VI. Synthesis of 2,4-diaminoquinazolines from anthranilonitriles.
    Journal of medicinal chemistry, 1970, Volume: 13, Issue:5

    Topics: Animals; Chemical Phenomena; Chemistry; Culture Techniques; Folic Acid Antagonists; Lactobacillus; Mice; Neoplasms, Experimental; Nitriles; ortho-Aminobenzoates; Quinazolines; Streptococcus

1970